Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series.
Authors
Umang Swami
University of Iowa Hospitals and Clinics, Iowa City, IA
Umang Swami, Varun Monga, Yousef Zakharia, Mohammed M. Milhem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Myeloid-Derived Suppressor Cells
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 123)
DOI
10.1200/JCO.2017.35.7_suppl.123
Abstract #
123
Poster Bd #
J3
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).
First Author: Douglas Buckner Johnson
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).
First Author: David B. Page
Poster
2016 ASCO Annual Meeting
Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.
First Author: MarnixMarnix Heimen Geukes Foppen
Poster
2016 ASCO Annual Meeting
Costs associated with adverse events for systemic therapies in metastatic melanoma.
First Author: Ying Qiu